<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04235673</url>
  </required_header>
  <id_info>
    <org_study_id>20180004210 17/01/2018</org_study_id>
    <nct_id>NCT04235673</nct_id>
  </id_info>
  <brief_title>Oral Melatonin as Neuroprotectant in Preterm Infants</brief_title>
  <official_title>Oral Melatonin as Neuroprotectant in Preterm Infants .A Prospective, Double Blind vs Placebo, Parallel Arms Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Francesca Garofoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IRCCS National Neurological Institute &quot;C. Mondino&quot; Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preterm newborns survival rates are improved, but long-term disabilities are still common.&#xD;
      Major destructive focal lesions became less common, the most predominant lesion at present is&#xD;
      diffuse white matter (WM damage). Melatonin (ME) serves as a neuroprotectant cerebral&#xD;
      ischemia through its potent anti-oxidant/-inflammatory effect. Preclinical studies&#xD;
      demonstrated that protects the developing brain by preventing abnormal myelination and&#xD;
      inflammatory glial reaction. Clinical studies demonstrated ME ability in reducing brain&#xD;
      damage after neonatal Hypoxic Ischemic Encephalopathy (HIE) or preventing neonatal&#xD;
      impairments due to antenatal/ post-natal injuries: preeclampsia,&#xD;
      IntraUterineGrowthRestriction (IUGR), ventilation, Bronchopulmonary Dysplasia (BPD). ME has a&#xD;
      good safety profile with no known adverse effects. This study aims to highlight that ME can&#xD;
      prevent brain impairment due to premature birth. ME will be administered orally (3 mg/kg/die&#xD;
      for 15 days to neonates born before 29+6 week gestation, in a prospective double blind,&#xD;
      randomized vs placebo study, 2 parallel arms. ME and malondialdehyde (MDA), a lipid&#xD;
      peroxidation product) levels before and at the end of treatment will be measured . Other&#xD;
      outcomes: Cerebral ultrasounds (cUS); cerebral magnetic resonance imaging (cMRI), &quot; Fagan&#xD;
      test &quot; eye tracking, ophthalmological, auditory, neurological/cognitive child assessments.&#xD;
      Monitoring parental distress, which can influence the neurodevelopmental outcome in preterms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 552.000 infants are born in Italy each year, 1% of them with gestational age under 30&#xD;
      weeks. Survival rates are improved, but long-term disabilities are still common. Major&#xD;
      destructive focal lesions became less common, the most predominant lesion at present is&#xD;
      diffuse white matter (WM damage). The prevention of neurodevelopmental impairment is a major&#xD;
      public health challenge and efforts are needed to test neuroprotective strategies. Melatonin&#xD;
      (ME) serves as a neuroprotectant cerebral ischemia through its potent&#xD;
      anti-oxidant/-inflammatory effect. Preclinical studies demonstrated that protects the&#xD;
      developing brain by preventing abnormal myelination and inflammatory glial reaction. Clinical&#xD;
      studies demonstrated ME ability in reducing brain damage after neonatal Hypoxic Ischemic&#xD;
      Encephalopathy (HIE) or preventing neonatal impairments due to antenatal/ post-natal&#xD;
      injuries: preeclampsia, IntraUterineGrowthRestriction (IUGR), ventilation, Bronchopulmonary&#xD;
      Dysplasia (BPD). Ongoing studies are testing in premature neonates and pregnant women its&#xD;
      neuroprotective properties. ME has a good safety profile with no known adverse effects.&#xD;
&#xD;
      This study aims to highlight that ME can prevent brain impairment due to premature birth. ME&#xD;
      will be administered orally (3 mg/kg/die for 15 days within 96 hours from birth) to neonates&#xD;
      born before 29+6 week gestation age (GA), in a prospective double blind, randomized vs&#xD;
      placebo study, 2 parallel arms (30 preterm infants each). ME and malondialdehyde (MDA, a&#xD;
      lipid peroxidation product) levels will be measured before and at the end of treatment. At&#xD;
      birth, within 40 weeks of neonatal age, at 4-6 and at 24 months of age the following&#xD;
      examinations are performed: Cerebral ultrasounds (cUS); cerebral magnetic resonance imaging&#xD;
      (cMRI), during natural sleep (i.e. adopting sleep deprivation and/or feeding protocols);&#xD;
      &quot;Fagan test&quot;eye tracking, ophthalmological, auditory brain stem evoked response (ABR),&#xD;
      neurological/cognitive child assessments. Monitoring parental distress, which can influence&#xD;
      the neurodevelopmental outcome in preterms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Malondialdehyde</measure>
    <time_frame>15 days</time_frame>
    <description>plasmatic concentration pg/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Melatonin</measure>
    <time_frame>15 days</time_frame>
    <description>plasmatic concentration pg/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cranial ultrasound (cUS) Assessment</measure>
    <time_frame>up to 40 weeks</time_frame>
    <description>to identify and score White Matter injuries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Magnetic Resonance Immaging (cMRI) Assessment</measure>
    <time_frame>up to 40 weeks</time_frame>
    <description>Identify and score White Matter injuries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Auditory brain stem evoked response (ABR) Assessments</measure>
    <time_frame>up to 40 weeks</time_frame>
    <description>Identify and score auditory diseases</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fagan Test of Infant Intelligence (FTII)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Measure the time ( minutes) to recognize unfamiliar versus familiar human faces to gauge visual-spatial encoding, attention, and working memory in infants.</description>
  </other_outcome>
  <other_outcome>
    <measure>Griffiths Mental Developmental Scales'Revised (GMDS-R)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The scales rate infant development across 5 main areas (locomotor, personal and social skills, hearing and language, eye and hand co-ordination, and performance), providing a general developmental quotient (DQ) of infants' abilities and 5 subscale quotients (SQ).</description>
  </other_outcome>
  <other_outcome>
    <measure>Child Behavior Checklist (CBCL) scales.</measure>
    <time_frame>up to 24 months</time_frame>
    <description>A self-rating scale to evaluate emotional, social, and behavioral problems in infants, according to the parents' evaluation.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Malondialdehyde</condition>
  <condition>Melatonin</condition>
  <arm_group>
    <arm_group_label>melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>melatonin oral drops; 3 mg/kg/day for 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral drops manufactured to mimic melatonin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>melatonin</intervention_name>
    <description>orally administered drops</description>
    <arm_group_label>melatonin</arm_group_label>
    <other_name>not reported</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>orally administered drops</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>not reported</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  preterm newborns gestational age GA &lt; 29+6 weeks + day&#xD;
&#xD;
          -  able to receive min 20ml/kg/day enteral nutrition, within 96 hours from birth&#xD;
&#xD;
          -  written informed consent by both the parents.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  preterm newborns GA &gt; 29+6 weeks + days&#xD;
&#xD;
          -  not able to receive enteral nutrition (min 20 ml/kg/die) within 96 hours of life&#xD;
&#xD;
          -  infants with genetic and/or congenital metabolic or chronic diseases&#xD;
&#xD;
          -  intraventricular hemorrhage (IVH) â‰¥ III,&#xD;
&#xD;
          -  parents refusing to sign a written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Weeks</minimum_age>
    <maximum_age>30 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chryssoula Tzialla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Policlinico S. Matteo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chryssoula Tzialla, MD</last_name>
    <phone>+39 0382 502604</phone>
    <email>c.tzialla@smatteo.pv.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francesca Garofoli, PhD</last_name>
    <phone>+39 0382 502865</phone>
    <email>lab.immunoneo@smatteo.pv.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Child and Adolescence Neuropsychiatry Unit, Children's Hospital &quot;Spedali Civili&quot; of Brescia, 25123 Brescia, Italy.</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Maria Fazzi, MD</last_name>
      <phone>+39 030 3995721</phone>
      <email>neuropsichiatria.infanzia.adolescenza@asst-spedalicivili.it</email>
    </contact>
    <contact_backup>
      <last_name>Patrizia Accorsi, MD</last_name>
      <phone>+39 030399.5726</phone>
      <email>segreteria.umbnpsi@spedalicivili.brescia.it</email>
    </contact_backup>
    <investigator>
      <last_name>Elisa Maria Fazzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrizia Accorsi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neonatal Intensive Care Unit, Children's Hospital, University Hospital &quot;Spedali Civili&quot; Brescia, 25123 Brescia, Italy.</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Aversa, MD</last_name>
      <phone>+390303996296</phone>
      <email>salvatore.aversa@asst-spedalicivili.it</email>
    </contact>
    <contact_backup>
      <last_name>Valeria Materia, MD</last_name>
      <phone>+390303996295</phone>
      <email>matevale81@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Salvatore Aversa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valeria Materia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mario Motta, Md</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Mondino</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Orcesi, MD</last_name>
      <phone>+39 0382 3801</phone>
      <email>simona.orcesi@mondino.it</email>
    </contact>
    <contact_backup>
      <last_name>Camilla Caporali, MD</last_name>
      <phone>+39 0382 3801</phone>
      <email>camilla.caporali@mondino.it</email>
    </contact_backup>
    <investigator>
      <last_name>Simona Orcesi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camilla Caporali, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Cociglio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cecilia Naboni, neurotherap</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Pichiecchio, MD Radiol</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neonatal Unit and NICU, Radiology, Clinical Chemistry Lab., Fondazione IRCCS Policlinico S. Matteo.</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chryssoula Tzialla, MD</last_name>
      <phone>+39 0382 502604</phone>
      <email>c.tzialla@smatteo.pv.it</email>
    </contact>
    <contact_backup>
      <last_name>Stefania Longo, MD</last_name>
      <phone>+39 0382 502704</phone>
      <email>s.longo@smatteo.pv.it</email>
    </contact_backup>
    <investigator>
      <last_name>Chryssoula Tzialla, MD NICU</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefania Longo, MD NICU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesca Garofoli, PhD NICU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisa Civardi, MD NICU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beatrice Grenci, MD NICU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simona Zanette, MD NICU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Micol Angelini, PhD NICU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camilla Pisoni, PsyD NICU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorenzo Preda, MD Dir Radiol</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Simoncelli, MD Radio</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentina Genovese, MD Radio</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elvis Lafe, MD Radio</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vittoria Rizzo, PhD ClinChem</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Francesca Garofoli</investigator_full_name>
    <investigator_title>PhD, Researcher, Co-PI,</investigator_title>
  </responsible_party>
  <keyword>Preterm neonate</keyword>
  <keyword>Neuroprotection</keyword>
  <keyword>Malondialdehyde</keyword>
  <keyword>Melatonin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

